F-star Shares Rise On Bispecific Antibody Therapeutics Pact With Janssen
F-star Therapeutics Ltd (NASDAQ:FSTX) has entered into a license and collaboration agreement with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ). Under…
F-star Therapeutics Reports License Deal With J&J’s Janssen To Develop, Commercialize Multiple Next Gen Bispecific Antibody Therapeutics; Co. To Receive Upfront Fees Of $17.5M, Near-Term Fees, Milestones Up To $1.35B
F-star Therapeutics, Ltd. (NASDAQ:FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives
10 Biggest Price Target Changes For Tuesday
Citigroup cut the price target on Wix.com Ltd. (NYSE: WIX) from $320 to $250. Wix.com shares fell 1.6% to close at $202.16 on Monday.
SVB Leerink Maintains Outperform on F-star Therapeutics, Lowers Price Target to $35
SVB Leerink analyst Daina Graybosch maintains F-star Therapeutics (NASDAQ:FSTX) with a Outperform and lowers the price target from $39 to $35.
F-star’s FS118 Development Program To Include Checkpoint Naïve Cancer Patients
F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients. The new study will…
F-star Therapeutics Q2 EPS $(0.92) Misses $(0.74) Estimate
F-star Therapeutics (NASDAQ: FSTX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.74) by 24.32 percent.F-star Therapeutics (NASDAQ:FSTX) reported quarterly losses of $(0.92) per share which missed the anal
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)